Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

Market Intel: Medtronic, Philips, Masimo, And Others Keep Pulse Beating In Oximetry Patient Monitoring Market

Demand for reliable, accurate, high-quality pulse oximetry devices in and – increasingly – outside hospitals is driven by the rise of chronic diseases, a growing elderly population prone to asthma, heart disease, sleep apnea and chronic obstructive pulmonary disease, as well as the need to monitor oxygen levels in premature babies. According to a new report by Meddevicetracker, the global market for standalone, hospital-grade pulse oximetry devices and accessories will reach $1.9bn by 2021, a CAGR of 5.4% from 2016. In this feature, we'll take a closer look at the overall pulse oximetry market, the major players and which forces are driving  and stymying  its growth.

Diagnostics Innovation Market Intelligence

Latest From Market Intelligence

QUOTED. March 13, 2018. Carla Kriwet.

Philips has developed a contactless pulse oximetry monitoring technology that has shown promise in a small patient study. Check out what Philips Patient Care & Monitoring Solutions CEO Carla Kriwet said about it here.

Quoted Diagnostics

QUOTED. March 5, 2018. Jon Hoem.

Check out what Corflow Therapeutics CEO Jon Hoem had to say about the unaddressed problem of microvascular obstruction in heart-attack patients.

Market Intelligence Innovation

Market Intel: Heart Attack Therapy Firms Seek Unobstructed Path For MVO Solutions

When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.

Cardiovascular Cardiology

QUOTED. Feb. 23, 2018. Anthony Arnold.

Anthony Arnold, CEO of device-maker SetPoint, says the drug industry is underestimating what patients really want when it comes to treating rheumatoid arthritis (RA). Check out what he said here.
Quoted Commercial

Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis

As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.

Inflammation Neurology

QUOTED. Feb. 7, 2018. Jay Shah.

Check out what Jay Shay, a pain medicine fellow at Weill-Cornell Tri-Institutional Pain Program in New York, had to say about spinal cord stimulation devices no longer being seen as a last-resort therapy for patients experiencing chronic, debilitating pain.
Quoted Neurology
See All